摘要
目的:探讨齐拉西酮与奥氮平治疗首发精神分裂症的临床疗效与安全性。方法:将64例首发精神分裂症患者随机分为齐拉西酮组32例与奥氮平组32例,治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:齐拉西酮组总有效率为84.4%,奥氮平组为87.5%,两组差异无显著性(P>0.05)。齐拉西酮组主要不良反应是失眠,奥氮平组是体质量增加和血糖升高。结论:齐拉西酮与奥氮平治疗首发精神分裂症均有良好疗效,2药不良反应均较轻。
Objective： To compare the efficacy and safety of ziprasidone and olanzapine in the treatment of first-episode schizophrenia. Method： Sixty-four patients with schizophrenia were randomly allocated to ziprasidone group （ n = 32） or olanzapine group （ n = 32 ） respectively, and the duration of treatment was 8 weeks. The positive and negative syndrome scale（PANSS） and treatment emergent side effect scale（TESS） were used to evaluate the efficacy and adverse effects. Results：The efficacy rates of ziprasidone and olanzapine were 84.4% and 87.5% respectively after 8 week＇ s treatment. There was no significant difference in the efficacy rates between the two groups （ P 〉 0.05 ）. The side effects of ziprasidone were insomnia, and those of olanzapine were increased weight and blood glucose levels. Conclusion： Ziprasidone is as effective and safe as olanzapine for the treatment of first-episode schizophrenia, and with fewer side effects.
出处
《临床精神医学杂志》
2008年第5期335-336,共2页
Journal of Clinical Psychiatry
